Published in Eur J Nucl Med on May 01, 1993
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging (2008) 2.74
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging (2004) 0.98
Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. Phys Med Biol (2012) 0.98
Accuracy and precision of radioactivity quantification in nuclear medicine images. Semin Nucl Med (2012) 0.96
Optimization and assessment of quantitative 124I imaging on a Philips Gemini dual GS PET/CT system. Eur J Nucl Med Mol Imaging (2009) 0.92
Correction technique for cascade gammas in I-124 imaging on a fully-3D, Time-of-Flight PET Scanner. IEEE Trans Nucl Sci (2009) 0.91
Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging. Mol Imaging Biol (2013) 0.90
Immuno-positron emission tomography in cancer models. Semin Nucl Med (2010) 0.88
Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. Phys Med Biol (2015) 0.85
Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively. Cancer Res (2014) 0.78
Monoclonal antibody ONS-M21 recognizes integrin alpha3 in gliomas and medulloblastomas. Br J Cancer (1999) 0.75
Positron emission tomography and the central nervous system. Arch Dis Child (1999) 0.75
Pfam 3.1: 1313 multiple alignments and profile HMMs match the majority of proteins. Nucleic Acids Res (1999) 11.64
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16
The genome of the simian and human malaria parasite Plasmodium knowlesi. Nature (2008) 3.02
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol (1987) 2.81
Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys (1989) 2.72
Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet (1993) 2.72
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol (1996) 2.59
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res (2001) 2.48
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg (1998) 2.32
Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer (1997) 2.20
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Resection of brain metastases from colorectal carcinoma in 73 patients. Cancer (1999) 2.16
Quality control procedure for 6-[18F]fluoro-L-DOPA: a presynaptic PET imaging ligand for brain dopamine neurons. J Nucl Med (1989) 2.04
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol (1999) 2.02
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90
The case for and technique of heterotopic liver grafting. Transplant Proc (1979) 1.87
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res (1985) 1.78
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 1.69
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg (1999) 1.67
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol (2001) 1.64
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
111Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology (1998) 1.59
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59
Small molecule nerve growth factor analogs image receptors in vivo. Nat Biotechnol (1996) 1.56
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49
FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49
Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A (1998) 1.48
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
Parthenogenesis of human oocytes as a function of vacuum pressure. J In Vitro Fert Embryo Transf (1989) 1.44
Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol (2001) 1.44
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer. Radiology (1999) 1.42
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med (1999) 1.42
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol (1991) 1.42
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med (1997) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review. Cancer (2001) 1.41
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Cyclophosphamide versus ifosfamide in paediatric oncology. Lancet (1990) 1.39
An assessment of monocyte procoagulant activity in patients with solid tumors. J Surg Res (1987) 1.37
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
Quantitative bone metastases analysis based on image segmentation. J Nucl Med (1997) 1.36
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys (2004) 1.35
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery (1987) 1.35
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
Spinal metastases from solid tumors. Analysis of factors affecting survival. Cancer (1995) 1.34
Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med (1971) 1.33
Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A (2000) 1.33
Pituitary gland metastases. Ann Surg Oncol (1996) 1.33
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum (2000) 1.32
Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst (1986) 1.31
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med (1998) 1.30
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci U S A (2000) 1.29
Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. J Clin Oncol (1990) 1.28
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol (1994) 1.26
Midazolam changes cerebral blood flow in discrete brain regions: an H2(15)O positron emission tomography study. Anesthesiology (1997) 1.25
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood (1989) 1.25
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (1999) 1.25
Postoperative radiation for lung cancer metastatic to the brain. J Clin Oncol (1994) 1.24
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24